Syndax Pharmaceuticals, Inc. (SNDX) The 67th American Society of Hematology (ASH) Annual Meeting December 8, 2025 7:00 AM EST
Company Participants
Michael Metzger – CEO & Director
Nicholas Botwood – Head of Research & Development and Chief Medical Officer
Conference Call Participants
Zachariah DeFilipp
David Sallman
Elias Jabbour
David Swoboda
Xiaochuan Dai – UBS Investment Bank, Research Division
Yuxi Dong – Jefferies LLC, Research Division
Philip Nadeau – TD Cowen, Research Division
Jeffrey Tan
Dara Azar – Stifel, Nicolaus & Company, Incorporated, Research Division
Conversation
Michael Metzger
CEO & Director
Good morning, everyone. So thanks for joining today. We’re excited to be here at ASH. Really exciting agenda today to walk through. And I’ll start by making some opening remarks, and then we’ll turn it over to our 4 esteemed thought leaders and PIs on our clinical trials. We’re excited to have them here today, and I’ll introduce them.
So these are the doctors, who have been working on our trials and helping us advance our programs for quite some time and making a difference for patients. First, in order, Dr. DeFilipp at MGH. So here we are at [indiscernible]. Right. So we’ll start off with Dr. DeFilipp. He’s the Director of Bone Marrow Transplant Clinical Research at MGH. He’ll talk about the latest data in chronic GVHD that we’re presenting here today this weekend. And then Nick is going to lead us in a panel discussion with him where we’ll be able to ask questions. There will be Q&A from the audience as well. And then we’ll turn it to Revuforj where we’ll have Dr. Sallman kick us off in looking at an overview of the treatment paradigm for acute leukemia, and he’ll present the first-of-its-kind real-world evidence for menin inhibitor. Dr Sallman as you know, is at Moffitt Cancer Center. And then we’ll move on to Dr. Jabbour. He’ll talk about our post-transplant maintenance data and save results from the frontline AML trial.
